Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-21 of 21 for your search:
Cancer Type/Condition:
Soft tissue sarcoma, child
Stage/Subtype:
recurrent childhood soft tissue sarcoma
Country:
U.S.A.
Trial Type:
Treatment
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
21 and under
Sponsor:
Other
Protocol IDs:
BMT 0499 Solid
, NCT00179816
2.
Phase I/II Study of Anti-IGF-1R Recombinant Monoclonal Antibody IMC-A12 and Doxorubicin Hydrochloride in Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
16 and over
Sponsor:
NCI
Protocol IDs:
UCCRC-16227A
, 16227A, 8131, NCT00720174
3.
Phase I/II Study of Dasatinib in Combination With Ifosfamide, Carboplatin, and Etoposide Phosphate in Young Patients With Metastatic or Recurrent Malignant Solid Tumors
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
1 to 25
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
CHNMC-07053
, 07053, CA180 121, NCT00788125
4.
Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
1 and over
Sponsor:
Other
Protocol IDs:
J0963
, NA_00028490, NCT00949325
5.
Phase I/II Study of Irinotecan and Temsirolimus in Patients With Refractory Sarcomas
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
10 and over
Sponsor:
Other
Protocol IDs:
INST 0909
, 3066K1, 3066K1-1208, 20091334, NCT00996346
6.
Phase II Pilot Study of Induction Chemotherapy Followed By Allogeneic/Syngeneic Peripheral Blood Stem Cell Transplantation in Patients With High-Risk, Recurrent Pediatric Sarcoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
4 to 35
Sponsor:
NCI
Protocol IDs:
NCI-02-C-0259
, NCT00047372
7.
Radiation Therapy to Treat Musculoskeletal Tumors
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
25 and under
Sponsor:
Other
Protocol IDs:
RTSARC
, NCT00186992
8.
Phase II Study of Intrathecal Iodine I 131 Monoclonal Antibody 3F8 in Patients With GD2-Expressing Central Nervous System or Leptomeningeal Neoplasms
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Any age
Sponsor:
Other
Protocol IDs:
MSKCC-05122
, NCT00445965
9.
Phase II Pilot Study of Irradiated Allogeneic Related Donor Lymphocyte Infusion in Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Any age
Sponsor:
NCI
Protocol IDs:
CINJ-3330
, NCT00161187
10.
Phase 2 Study in Patients With MiT Tumors
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
13 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
ARQ 197-204
, NCT00557609
11.
Proton Radiation for the Treatment of Pediatric Bone and Non-Rhabdomyosarcoma Soft Tissue Sarcomas
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
30 and under
Sponsor:
NCI, Other
Protocol IDs:
05-326
, NCT00592293
12.
A Five-Tier, Phase 2 Open-Label Study of IMC-A12 Administered as a Single Agent
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
12 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CP13-0707
, EudraCT Number: 2007-006719-21, NCT00668148
13.
Phase II Study of Cixutumumab in Patients With Relapsed or Refractory Solid Tumors
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
6 months to 30 years
Sponsor:
NCI
Protocol IDs:
COG-ADVL0821
, ADVL0821, NCT00831844
14.
Phase I Study of Ixabepilone in Young Patients With Refractory Solid Tumors (Closed to Accrual as of 10/4/2007) or Relapsed or Refractory Leukemia
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
2 to 21
Sponsor:
NCI
Protocol IDs:
NCI-02-C-0031
, 02-C-0031, 5425, NCI-5425, NCT00030108
15.
Phase I Study of Intrathecal Iodine I 131 Monoclonal Antibody 8H9 in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
Any age
Sponsor:
NCI
Protocol IDs:
MSKCC-03133
, NCT00089245
16.
Phase I Study of Cediranib in Pediatric Patients With Refractory or Recurrent Extracranial Malignant Solid Tumors or Acute Myeloid Leukemia
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
2 to 18
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
NCI-06-C-0152
, NCI-P6571, NCT00354848, ZENECA-D8480C00016
17.
Phase I Study of Lexatumumab With or Without Recombinant Interferon Gamma in Pediatric Patients With Relapsed or Refractory Solid Tumors or Lymphoma
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
1 to 30
Sponsor:
NCI
Protocol IDs:
NCI-07-C-0040
, NCI-P6981, NCT00428272
18.
Phase I Study of Ipilimumab (Anti-CTLA-4) in Children, Adolescents, and Young Patients With Advanced or Refractory Solid Tumors
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
2 to 21
Sponsor:
NCI
Protocol IDs:
NCI-08-C-0007
, 08-C-0007, NCI-P6068, 7458, NCT00556881
19.
Phase I Study of Total Marrow Irradiation With Helical Tomotherapy Image-Guided Intensity-Modulated Radiotherapy Followed by Alkylator-Intense Conditioning Comprising Busulfan, Melphalan, and Thiotepa and Autologous CD34+ Hematopoietic Progenitor Cell Transplantation in Patients With High-Risk or Relapsed Solid Tumors
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Diagnostic, Treatment
Status:
Active
Age:
70 and under
Sponsor:
NCI
Protocol IDs:
UMN-2005LS023
, UMN-2005LS023, UMN-MT2004-30, NCT00623077
20.
Phase I Study of Pazopanib Hydrochloride in Pediatric Patients With Refractory Solid Tumors
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
1 to 21
Sponsor:
NCI
Protocol IDs:
COG-ADVL0815
, ADVL0815, NCT00929903
21.
Pilot Study of Cyclophosphamide and Cryoablation in Patients With Advanced or Metastatic Epithelial Solid Cancer
Phase:
No phase specified
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Over 18
Sponsor:
NCI
Protocol IDs:
JHOC-J0685
, NA_00003073, J0685, NCT00499733
Select All on Page
Help with Results
